In their Article, Hussein Tawbi and colleagues¹ suggest that pembrolizumab might have clinical activity in patients with undifferentiated pleomorphic sarcoma or dedifferentiated liposarcoma. However, the SARC028 trial was not designed to specifically assess the activity of pembrolizumab in undifferentiated pleomorphic sarcoma or dedifferentiated liposarcoma, and this study was negative for its primary endpoint.

中文翻译：

---

肉瘤中PD-1抑制作用仍需研究

侯赛因·塔比（Hussein Tawbi）及其同事¹在他们的文章中建议，派姆单抗在未分化的多形性肉瘤或未分化的脂肪肉瘤患者中可能具有临床活性。但是，SARC028试验的目的不是专门评估派姆单抗在未分化多形性肉瘤或去分化脂肪肉瘤中的活性，该研究的主要终点为阴性。